Pilot Study for Patients With Poor Response to Deferasirox

Part I: Inclusion criteria for Inadequate responders * Male or female patients with transfusion dependent iron overload including patients with thalassemia syndromes, sickle cell disease and bone marrow failure. * Patients currently on Desferal (desferrioxamine) therapy will require a one day wash out prior to the first dose of study drug. * Dose of deferasirox: \>30 mg/kg/day of deferasirox for at least 3 months * No improvement or worsening of liver iron content (LIC) if this has been evaluated on deferasirox in the 3 months preceding the baseline studies. * Age greater than 6 years * Serum Ferritin: Ferritin \>1500 ng/ml and rising over three month period while on deferasirox. * Patients had to achieve 'failure' as described above previously and may or may not currently be on deferasirox and may currently be having adequate responses on doses greater than or equal to 35 mg/kg/day of deferasirox. * Life expectancy ≥ 6 months * Written informed consent by the patient or for pediatric patients consent of the patient's legal guardian. The definition of the term 'pediatric' for enrollment and study conduct will be in accordance with Children's Hospital IRB. Parents or the legal guardians will be fully informed by the investigator as to the requirements of the study. Pediatric patients themselves will be informed according to their capabilities in a language and in terms that they are able to understand. Written informed consent will be obtained from their legal guardian on the…